Virologic factors related to interferon-alpha-induced thyroid dysfunction in patients with chronic hepatitis C

Department of Internal Medicine, Koahsiung Medical University, Koahsiung, Taiwan, Republic of China.

OBJECTIVE: Hepatitis C virus (HCV), being reported to be associated with a high prevalence of serological markers of autoimmunity in HCV-infected patients, and possibly sharing partial sequences in amino acid segments with thyroid tissue antigens, may be associated with interferon-alpha (IFN-alpha)-induced thyroid dysfunction in chronic hepatitis C patients. We conducted this study to clarify the issue. DESIGN AND METHODS: One hundred and fifty chronic hepatitis C patients with normal baseline thyroid function were treated with IFN-alpha 2a, 2b and n1 (3-6 million Units three times weekly for 24 weeks). Pretreatment sera were tested for HCV genotype and HCV RNA levels. Serum thyrotropin, total thyroxine and free thyroxine index were performed every 4 weeks for 24 weeks followed by every 8 weeks for another 24 weeks. RESULTS: Twenty-one (14.0%) patients developed early thyroid dysfunction (abnormal thyroid function during the first 3 months of therapy). Female gender, lower HCV RNA levels, IFN-alpha n1 and a lower IFN-alpha dose were significantly associated with early thyroid dysfunction. On multivariate analysis, gender, IFN-alpha preparation and HCV RNA levels were the significant factors associated with early thyroid dysfunction. Seven (4.7%) patients developed thyroid dysfunction during the second 3 months of IFN-alpha therapy. Taken together, 18.7% patients developed thyroid dysfunction. Female, mixed HCV genotype infection and lower HCV RNA levels were significantly associated with thyroid dysfunction. However, only gender remained significantly associated with IFN-alpha-induced thyroid dysfunction in multivariate analysis. CONCLUSIONS: The virologic features of HCV may be associated with thyroid dysfunction in chronic hepatitis C patients treated with IFN-alpha. Nevertheless, gender still plays the most important role in IFN-alpha-induced thyroid dysfunction.

This article has been cited by other articles:

				H.A. Tran, G.E.M. Reeves, and T.L. Jones The natural history of interferon-{alpha}2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection QJM, November 25, 2008; (2008) hcn150v1. [Abstract] [Full Text] [PDF]

				M-Y Hsieh, C-Y Dai, L-P Lee, J-F Huang, W-C Tsai, N-J Hou, Z-Y Lin, S-C Chen, L-Y Wang, W-Y Chang, et al. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C J. Clin. Pathol., March 1, 2008; 61(3): 333 - 337. [Abstract] [Full Text] [PDF]

				M. Rotondi, R. Minelli, F. Magri, P. Leporati, P. Romagnani, M. C. Baroni, R. Delsignore, M. Serio, and L. Chiovato Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-{alpha} therapy for hepatitis C virus-related hepatitis Eur. J. Endocrinol., April 1, 2007; 156(4): 409 - 414. [Abstract] [Full Text] [PDF]

				E. J. Bini and S. Mehandru Incidence of Thyroid Dysfunction During Interferon Alfa-2b and Ribavirin Therapy in Men With Chronic Hepatitis C: A Prospective Cohort Study Arch Intern Med, November 22, 2004; 164(21): 2371 - 2376. [Abstract] [Full Text] [PDF]

				C. Carella, G. Mazziotti, G. Amato, L. E. Braverman, and E. Roti Interferon-{alpha}-Related Thyroid Disease: Pathophysiological, Epidemiological, and Clinical Aspects J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3656 - 3661. [Full Text] [PDF]

				A. Antonelli, C. Ferri, P. Fallahi, D. Giuggioli, C. Nesti, G. Longombardo, P. Fadda, A. Pampana, M. Maccheroni, and E. Ferrannini Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia QJM, August 1, 2004; 97(8): 499 - 506. [Abstract] [Full Text] [PDF]

				W. B. Chan, C. C. Chow, and C. S. Cockram Interferon alpha treatment and endocrine disease J R Soc Med, October 1, 2003; 96(10): 481 - 485. [Full Text] [PDF]